Evidence map›Paper›PMID 25755728›Full record

ArticleInternational journal of clinical and experimental pathology2015

Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis.

Mona Diab-Assaf, Raefa Abou-Khouzam, Nina Saadallah-Zeidan, Khaled Habib, Nizar Bitar, Walid Karam, Bertrand Liagre, Steve Harakeh, Rania Azar

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Clinical Significance of Eukaryotic Initiation Factor 4E (eIF4E) Level among Cases Suffering Basal Cell Carcinoma of Skin.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Mona Diab-AssafMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University Hadath, Lebanon.
Raefa Abou-KhouzamMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University Hadath, Lebanon.
Nina Saadallah-ZeidanMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University Hadath, Lebanon.
Khaled HabibSpecialized Medical Laboratory Al-Mazraa, Beirut, Lebanon.
Nizar BitarFaculty of Medicine, Lebanese University Hadath, Lebanon.
Walid KaramMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University Hadath, Lebanon.
Bertrand LiagreBiochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, University of Limoges FR 3503 GEIST, EA1069, GDR CNRS 3049, Limoges, France.
Steve HarakehSpecial Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University Kingdom of Saudi Arabia.
Rania AzarMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University Hadath, Lebanon.
Lebanese University · LBCentre National de la Recherche Scientifique · FRKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cap dependent translation is mainly regulated at the level of the eukaryotic initiation factor 4E (eIF4E), the activity of which is controlled by phosphorylation and sequestration by its well established regulator, 4E binding protein 1 (4E-BP1). Both eIF4E and 4E-BP1 have been shown to be involved in the malignant progression of multiple human cancers, including colorectal cancer. However, the data on determining the expression of eIF4E, 4E-BP1 and their phosphorylated forms simultaneously in a single patient with colorectal cancer is lacking. Therefore the aim of our study was to explore the roles of these factors in colorectal carcinogenesis by immunohistostaining colorectal tissues (normal, low grade adenoma, high grade adenoma, and adenocarcinoma). Our results showed that the expression levels of eIF4E increased steadily as the cancer progressed from the case of benign dysplasia to an adenocarcinoma; all the while maintaining an unphosphorylated form. On the other hand, total expression levels of 4E-BP1 increased only in the premalignant state of the disease and decreased (but highly phosphorylated or inactivated) or abolished upon malignancy. Taken together, our findings suggest that strong correlations exist between the expression of eIF4E (not p-eIF4E) and tumor grade providing evidence that eIF4E expression plays a pivotal role in the malignant progression of colorectal cancer. Moreover, 4E-BP1 showed a bi-phasic level of expression during carcinogenesis, which is expressed only in hyperplasic or dysplastic tissues as an endogenous tumor suppressor molecule.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaAdenomaCarcinogenesisCell Cycle ProteinsColonColorectal NeoplasmsDisease ProgressionEukaryotic Initiation Factor-4EHumansNeoplasm GradingPhosphoproteinsPhosphorylationAdaptor Proteins, Signal TransducingCell Cycle ProteinsEIF4EBP1 protein, humanEukaryotic Initiation Factor-4EPhosphoproteins4E-BP1Colorectal cancereIF4Eimmunuhistochemistrytranslational control

Identifiers

PMID25755728
PMCPMC4348849
OpenAlexW2406488378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.